Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 69.3267
- Book/Share 43.6271
- PB 5.7562
- Debt/Equity 0.6749
- CurrentRatio 0.7996
- ROIC 0.295
- MktCap 1116697634030.579
- FreeCF/Share 12.6317
- PFCF 19.8757
- PE 10.9301
- Debt/Assets 0.2412
- DivYield 0.0311
- ROE 0.6096
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVO | JP Morgan | Overweight | Neutral | -- | -- | Feb. 24, 2026 |
| Downgrade | NVO | Kepler | Buy | Hold | -- | -- | Feb. 24, 2026 |
| Downgrade | NVO | Deutsche Bank | Buy | Hold | -- | -- | Feb. 23, 2026 |
| Upgrade | NVO | Jefferies | Underperform | Hold | -- | -- | Feb. 12, 2026 |
| Initiation | NVO | Citigroup | -- | Neutral | -- | -- | Jan. 27, 2026 |
| Downgrade | NVO | Argus | Buy | Hold | -- | -- | Dec. 8, 2025 |
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
News
Ozempic Price War - Novo Nordisk Slashes Prices By 50%
Published: February 25, 2026 by: Benzinga
Sentiment: Negative
Novo Nordisk A/S (NYSE: NVO) shares are down during Wednesday's premarket session. The down move comes as the company announced plans to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027, adding pressure as broader markets edged lower.
Read More
Healthy Returns: What's next for Novo Nordisk's next-generation obesity drug CagriSema after trial miss
Published: February 24, 2026 by: CNBC
Sentiment: Negative
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly's Zepbound.
Read More
Ozempic, Wegovy prices to drop up to 50% as Novo Nordisk's rivalry with Eli Lilly heats up: report
Published: February 24, 2026 by: New York Post
Sentiment: Negative
Drugmaker Novo Nordisk plans to slash list prices for its wildly popular weight-loss and diabetes drugs Wegovy and Ozempic by as much as 50%, according to a report.
Read More
Novo Nordisk to slash list prices of Ozempic, Wegovy by up to 50%
Published: February 24, 2026 by: Fox Business
Sentiment: Neutral
Novo Nordisk announced up to 50% price cuts for Ozempic and Wegovy diabetes and weight-loss drugs starting January 2027, lowering costs to $675 per dose.
Read More
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Neutral
LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.
Read More
Anthropic's enterprise showcase impressed the room but is the AI threat to software stocks remains largely a ghost story?
Published: February 24, 2026 by: Proactive Investors
Sentiment: Positive
The demos were real. The use cases were compelling.
Read More
Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound
Published: February 24, 2026 by: Proactive Investors
Sentiment: Negative
The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's post-Ozempic strategy, with analysts slashing price targets and two major banks walking away from bullish positions Novo Nordisk's (NYSE:NVO) last best hope for life after semaglutide has stumbled badly. The Danish drugmaker's CagriSema combination jab failed on Monday to demonstrate non-inferior weight loss against Eli Lilly's Zepbound in the REDEFINE-4 phase III trial, a result that has prompted two high-profile analyst downgrades and forced a broad reassessment of the company's long-term earnings power.
Read More
Novo Nordisk: Why Wegovy Growth Beats Wall Street Expectations
Published: February 23, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk shares have fallen 16.4% over the past six months. However, I believe Wall Street is still underestimating the prospects of semaglutide at a dose of 25 mg. Even excluding its approval in late December last year, Wegovy generated DKK 79.1 billion in net revenues for Novo Nordisk in 2025, a 35.9% increase year-on-year.
Read More
5 Things to Know Before the Stock Market Opens
Published: February 23, 2026 by: Investopedia
Sentiment: Negative
Stocks are pointing to a lower open amid tariff uncertainty after major indexes posted gains last week; President Donald Trump is imposing new tariffs to replace the ones the Supreme Court struck down on Friday, starting with a 15% global tariff; earnings from Nvidia, Home Depot, Lowe's, Salesforce and other major companies headline a busy week that will also include Trump's State of the Union address; Novo Nordisk shares are slumping after the Ozempic and Wegovy maker disappointed in its latest clinical trial for its next-generation weight-loss drug; and thousands of flights are being delayed or canceled across the East …
Read More
Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value
Published: February 23, 2026 by: Proactive Investors
Sentiment: Negative
Novo Nordisk (NYSE:NVO) attempt to reclaim the initiative in the obesity drug race has backfired, after its experimental next-generation treatment failed to prove it was as effective as a rival therapy from Eli Lilly. The Danish drugmaker's shares were off 14% ahead of the bell in the US (it fell as much as 15% in Europe), after it disclosed that CagriSema did not meet its primary objective of demonstrating non-inferiority to Lilly's tirzepatide in terms of weight loss over 84 weeks.
Read More
Novo Nordisk A/S (NOVO:CA) Discusses Top Line Results of REDEFINE 4 Phase III Obesity Trial Comparing CagriSema and Tirzepatide Transcript
Published: February 23, 2026 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk A/S (NOVO:CA) Discusses Top Line Results of REDEFINE 4 Phase III Obesity Trial Comparing CagriSema and Tirzepatide Transcript
Read More
Novo Nordisk slump wipes out last Wegovy-era gains after trial setback
Published: February 23, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk shares fell more than 15% on Monday, wiping away the last gains Wegovy's launch had brought, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's tirzepatide in a trial.
Read More
Novo Nordisk Shares Slide After Obesity Drug Misses Key Goal in Trial
Published: February 23, 2026 by: WSJ
Sentiment: Negative
Shares fell sharply after the Danish drugmaker said its CagriSema experimental obesity drug failed to beat the weight loss delivered by Eli Lilly's Zepbound in a head-to-head clinical trial.
Read More
Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost
Published: February 23, 2026 by: Market Watch
Sentiment: Negative
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut as much weight as an Eli Lilly product.
Read More
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial
Published: February 23, 2026 by: CNBC
Sentiment: Negative
The drug, CagriSema, didn't achieve its primary endpoint of demonstrating non-inferiority on weight loss. In this article NVO
Read More
Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial
Published: February 23, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly's Tirzepatide in reducing body weight.
Read More
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved
Published: February 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 23 February 2026 – Novo Nordisk today announced headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial programme.
Read More
EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
NVO wins EU nod for a higher 7.2 mg Wegovy dose, unlocking stronger weight-loss results and a new step-up option for obesity care.
Read More
Novo Nordisk: The Possible Upside
Published: February 17, 2026 by: Seeking Alpha
Sentiment: Neutral
Weight loss treatments provider Novo Nordisk might have experienced a sharp stock decline after disappointing 2025 results and 2026 outlook, but it has seen an impressive bounce back since. While the expected financial weakness is a real downer, there's a possibility of a sales surprise this year considering the company's recent vigorous actions as well as promising launches. NVO's forward P/E has fallen so low now that further upside looks unmistakable. This is especially true as the company is expected to return to improved financial health from 2027.
Read More
Novo Nordisk's Wegovy Weight Loss Shot Approved at Higher Dose in EU
Published: February 17, 2026 by: WSJ
Sentiment: Positive
Patients on the higher dose of 7.2 milligrams for about 18 months lost 21% of their body weight on average, a study found.
Read More
EU approves higher dose of Novo's Wegovy
Published: February 17, 2026 by: Reuters
Sentiment: Positive
The European Commission has approved a higher dose of Novo Nordisk's popular weight-loss drug Wegovy, the Danish drugmaker said on Tuesday.
Read More
NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk stock sinks 21% in a month as weak 2026 guidance, slowing semaglutide sales, and rising competition overshadow relatively strong Q4 results.
Read More
Novo Nordisk plans Wegovy vials amid obesity-drug competition
Published: February 12, 2026 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) announced that it is planning to introduce its weight-loss medication Wegovy in vials. “We are exploring various device presentations for Wegovy, including vials—some are launching this year, others are coming in the future,” the company said.
Read More
Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market
Published: February 12, 2026 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S (NYSE: NVO) plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to strengthen its position against rival Eli Lilly and Co. (NYSE: LLY) as competition intensifies in the fast-growing weight-loss market.
Read More
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: February 11, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 11 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Read More
Novo Nordisk faces a defining year in the obesity drug market. It's off to a dramatic start
Published: February 11, 2026 by: CNBC
Sentiment: Neutral
Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what's been described as a “show me” year. The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share in the blockbuster weight loss drug market.
Read More
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
Published: February 11, 2026 by: CNBC
Sentiment: Positive
Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn't expect Medicare access to obesity treatments, expected later this year, to open up overnight.
Read More
Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Negative
NVO expects to face a shaky 2026 as Ozempic and Wegovy sales slow down and guidance signals decline despite a milestone oral Wegovy launch.
Read More
Novo Nordisk: How Low Is Too Low? (Downgrade, Technical Analysis)
Published: February 10, 2026 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S has seen its stock fall sharply, driven by a dramatic slowdown in EPS growth and weak 2026 guidance. A large drop was justified. This article looks at whether it could be overdone. Technical analysis suggests potential support at $36.80 and $29, which would be back to 2018-2020 levels. The company has grown significantly since then.
Read More
Novo Nordisk: Ugly Guidance, But Stock Refuses To Break Down Further
Published: February 10, 2026 by: Seeking Alpha
Sentiment: Neutral
Keeping my Buy rating on Novo Nordisk A/S despite a disappointing negative 2026 sales guidance amid fierce competition from Eli Lilly and compounders. NVO's Wegovy pill launch shows encouraging early uptake, with supply chain issues resolved and direct channel traction building. I reckon management's conservative 2026 outlook aims to reset expectations, positioning NVO for a potential re-rating as execution potentially improves from 2027.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406